Blood Cancer Journal - Table of Contents alert Volume 5 November 2015

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 5, November 2015 In this issue Review Original Article Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.The journal has an Impact Factor of 3.467. Explore the benefits of submitting your next research article. Review Top Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors S Cerquozzi and A Tefferi Blood Cancer J 2015 5: e366; 10.1038/bcj.2015.95 Abstract | Full Text Original Article Top Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) D C Phillips, Y Xiao, L T Lam, E Litvinovich, L Roberts-Rapp, A J Souers and J D Leverson Blood Cancer J 2015 5: e368; 10.1038/bcj.2015.88 Abstract | Full Text Letters to the Editor Top Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia T Barbui, A M Vannucchi, V Buxhofer-Ausch, V De Stefano, S Betti, A Rambaldi, E Rumi, M Ruggeri, F Rodeghiero, M L Randi, I Bertozzi, H Gisslinger, G Finazzi, A Carobbio, J Thiele, F Passamonti, C Falcone and A Tefferi Blood Cancer J 2015 5: e369; 10.1038/bcj.2015.94 Full Text An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome M Martini, S Capodimonti, M G Iachininoto, A Cocomazzi, E R Nuzzolo, M T Voso, L Teofili and L M Larocca Blood Cancer J 2015 5: e370; 10.1038/bcj.2015.97 Abstract | Full Text Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers L Ysebaert, E Laprévotte, C Klein and A Quillet-Mary Blood Cancer J 2015 5: e367; 10.1038/bcj.2015.93 Full Text Advertisement Nature Publishing Group offers a free open access funding support service to enable authors to discover and apply for article processing charge funding available to them. Visit our website for further advice on the funding options available, and guidance in approaching funders and institutions, or email openaccess@nature.com for more information.  You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.